Inventor
CHENG XIPING
US11 patents
Patents
11 patentsUS10961583B2Mar 30, 2021
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA9 citations82
US10787647B2Sep 29, 2020
HSD17B13 variants and uses thereof
REGENERON PHARMA10 citations81
US11845963B2Dec 19, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11753628B2Sep 12, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11702700B2Jul 18, 2023
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA4 citations71
US11180757B1Nov 23, 2021
17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA3 citations71
US11485958B2Nov 1, 2022
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations70
US12139546B2Nov 12, 2024
Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
REGENERON PHARMA0 citations62
US12359201B2Jul 15, 2025
17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA0 citations61
US12250931B2Mar 18, 2025
Genetically modified mouse with a humanized PNPLA3 gene and methods of use
REGENERON PHARMA0 citations60
US12286677B2Apr 29, 2025
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA0 citations59